Free Trial

Minerva Neurosciences (NERV) Competitors

Minerva Neurosciences logo
$1.64 -0.01 (-0.61%)
Closing price 07/7/2025 04:00 PM Eastern
Extended Trading
$1.65 +0.01 (+0.61%)
As of 07/7/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NERV vs. KLRS, BLUE, ADVM, VRCA, DTIL, AADI, ATRA, RNXT, VTVT, and APLT

Should you be buying Minerva Neurosciences stock or one of its competitors? The main competitors of Minerva Neurosciences include Kalaris Therapeutics (KLRS), bluebird bio (BLUE), Adverum Biotechnologies (ADVM), Verrica Pharmaceuticals (VRCA), Precision BioSciences (DTIL), Aadi Bioscience (AADI), Atara Biotherapeutics (ATRA), RenovoRx (RNXT), vTv Therapeutics (VTVT), and Applied Therapeutics (APLT). These companies are all part of the "pharmaceutical products" industry.

Minerva Neurosciences vs. Its Competitors

Minerva Neurosciences (NASDAQ:NERV) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

Minerva Neurosciences' return on equity of -20.68% beat Kalaris Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Minerva NeurosciencesN/A -20.68% 15.73%
Kalaris Therapeutics N/A -62.08%-54.69%

Minerva Neurosciences presently has a consensus price target of $5.00, suggesting a potential upside of 204.88%. Given Minerva Neurosciences' stronger consensus rating and higher possible upside, analysts plainly believe Minerva Neurosciences is more favorable than Kalaris Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Minerva Neurosciences
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Kalaris Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Minerva Neurosciences had 1 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 1 mentions for Minerva Neurosciences and 0 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 0.00 beat Minerva Neurosciences' score of -0.40 indicating that Kalaris Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Minerva Neurosciences Neutral
Kalaris Therapeutics Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Minerva NeurosciencesN/AN/A$1.44M$0.822.00
Kalaris TherapeuticsN/AN/A-$58.77MN/AN/A

Minerva Neurosciences has a beta of -0.34, suggesting that its share price is 134% less volatile than the S&P 500. Comparatively, Kalaris Therapeutics has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500.

34.6% of Minerva Neurosciences shares are owned by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are owned by institutional investors. 8.6% of Minerva Neurosciences shares are owned by company insiders. Comparatively, 75.0% of Kalaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Minerva Neurosciences beats Kalaris Therapeutics on 6 of the 10 factors compared between the two stocks.

Get Minerva Neurosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NERV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NERV vs. The Competition

MetricMinerva NeurosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$11.54M$2.43B$5.52B$9.02B
Dividend YieldN/A1.78%5.24%4.08%
P/E Ratio2.008.7527.1920.04
Price / SalesN/A473.55395.22100.83
Price / Cash7.9021.7726.2128.59
Price / Book-0.454.497.925.55
Net Income$1.44M$31.26M$3.17B$248.49M
7 Day Performance-1.80%1.27%1.79%4.87%
1 Month Performance-10.33%2.46%1.28%6.63%
1 Year Performance-47.10%-0.29%33.32%20.38%

Minerva Neurosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NERV
Minerva Neurosciences
3.9232 of 5 stars
$1.64
-0.6%
$5.00
+204.9%
-47.1%$11.54MN/A2.009Gap Up
KLRS
Kalaris Therapeutics
N/A$2.67
+1.9%
N/AN/A$49MN/A0.00110Positive News
Gap Up
BLUE
bluebird bio
2.0786 of 5 stars
$4.97
flat
$44.60
+797.4%
N/A$48.67M$103.95M-0.13520
ADVM
Adverum Biotechnologies
4.0469 of 5 stars
$2.15
-7.3%
$23.80
+1,007.0%
-67.6%$48.47M$1M-0.34190
VRCA
Verrica Pharmaceuticals
3.6006 of 5 stars
$0.53
+1.4%
$8.00
+1,409.1%
-89.1%$48.34M$7.57M-0.4440
DTIL
Precision BioSciences
4.4876 of 5 stars
$4.20
-2.3%
$47.00
+1,019.0%
-53.2%$47.68M$68.70M-2.09200
AADI
Aadi Bioscience
0.6347 of 5 stars
$1.93
+1.6%
$1.67
-13.6%
+49.6%$47.67M$25.07M-0.8540
ATRA
Atara Biotherapeutics
4.0778 of 5 stars
$7.72
-3.0%
$17.75
+129.9%
+3.6%$47.45M$128.94M-2.08330Gap Down
RNXT
RenovoRx
2.8749 of 5 stars
$1.32
+2.7%
$7.25
+451.3%
+16.3%$46.81M$40K-3.296Positive News
VTVT
vTv Therapeutics
1.9501 of 5 stars
$15.00
+3.5%
$35.50
+136.7%
-14.1%$46.29M$1.02M-4.989
APLT
Applied Therapeutics
3.7598 of 5 stars
$0.31
-3.9%
$6.10
+1,860.8%
-92.6%$45.84M$460K-0.7230Gap Up

Related Companies and Tools


This page (NASDAQ:NERV) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners